Several brokerages have updated their recommendations and price targets on shares of Nurix Therapeutics (NASDAQ: NRIX) in the ...

Morgan Stanley analyst Terence Flynn raised the firm’s price target on Nurix Therapeutics (NRIX) to $17 from $16 and keeps an Equal Weight ...

Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on Nurix Therapeutics (NRIX – Research Report) today. The company’s ...

Investment analysts at HC Wainwright cut their Q1 2025 earnings estimates for shares of Nurix Therapeutics in a research report issued on Wednesday, January 29th. HC Wainwright analyst R. Burns now ...

Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company specializing in protein degradation therapies, has been ...

About Nurix Therapeutics, Inc. Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation ...

Nurix Therapeutics, Inc. has appointed John Northcott as its new chief commercial officer, bringing over 20 years of experience in biotechnology commercialization. His background includes ...

8 analysts have expressed a variety of opinions on Nurix Therapeutics NRIX over the past quarter, offering a diverse set of opinions from bullish to bearish. In the table below, you'll find a ...

SAN FRANCISCO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ...